TauC3 Biologics is committed to engagement with scientific, medical and industry stakeholders in pursuit of our vision.
Keep up with our journey below.
NEW YORK AND LONDON, FEBRUARY 11, 2020
TAUC3 BIOLOGICS LIMITED, a newly established privately held British biopharmaceutical company developing an innovative immunotherapy with the demonstrated potential to prevent the spread of tau pathology in the brain, today announced the appointments of Andrew J. Heath, MD, PhD, as Non-Executive Chairman of its Board of Directors and Shafique Virani, MD as Non-Executive Director…
NEW YORK AND LONDON, APRIL 18, 2019
TAUC3 BIOLOGICS LIMITED announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3)…